vs
Side-by-side financial comparison of Arbutus Biopharma Corp (ABUS) and ECB Bancorp, Inc. (ECBK). Click either name above to swap in a different company.
Arbutus Biopharma Corp is the larger business by last-quarter revenue ($10.7M vs $9.5M, roughly 1.1× ECB Bancorp, Inc.). ECB Bancorp, Inc. runs the higher net margin — 27.3% vs 23.5%, a 3.8% gap on every dollar of revenue. On growth, Arbutus Biopharma Corp posted the faster year-over-year revenue change (522.2% vs 33.8%). Over the past eight quarters, ECB Bancorp, Inc.'s revenue compounded faster (23.8% CAGR vs -13.2%).
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
ECB Bancorp, Inc. (MD) is a US-based bank holding company. It offers a full suite of retail and commercial banking products including deposit accounts, consumer loans, commercial financing and wealth management solutions, primarily serving individuals and small-to-mid enterprises across local markets in Maryland.
ABUS vs ECBK — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.7M | $9.5M |
| Net Profit | $2.5M | $2.6M |
| Gross Margin | — | — |
| Operating Margin | 13.9% | 36.7% |
| Net Margin | 23.5% | 27.3% |
| Revenue YoY | 522.2% | 33.8% |
| Net Profit YoY | 112.7% | 79.5% |
| EPS (diluted) | $0.01 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $9.5M | ||
| Q3 25 | — | $8.8M | ||
| Q2 25 | $10.7M | $8.0M | ||
| Q1 25 | — | $6.9M | ||
| Q4 24 | — | $7.1M | ||
| Q3 24 | — | $6.6M | ||
| Q2 24 | — | $6.3M | ||
| Q1 24 | — | $6.2M |
| Q4 25 | — | $2.6M | ||
| Q3 25 | — | $2.4M | ||
| Q2 25 | $2.5M | $1.4M | ||
| Q1 25 | — | $1.3M | ||
| Q4 24 | — | $1.4M | ||
| Q3 24 | — | $1.1M | ||
| Q2 24 | — | $791.0K | ||
| Q1 24 | — | $621.0K |
| Q4 25 | — | 36.7% | ||
| Q3 25 | — | 37.0% | ||
| Q2 25 | 13.9% | 23.9% | ||
| Q1 25 | — | 24.9% | ||
| Q4 24 | — | 27.3% | ||
| Q3 24 | — | 23.3% | ||
| Q2 24 | — | 16.9% | ||
| Q1 24 | — | 13.4% |
| Q4 25 | — | 27.3% | ||
| Q3 25 | — | 27.7% | ||
| Q2 25 | 23.5% | 18.0% | ||
| Q1 25 | — | 18.7% | ||
| Q4 24 | — | 20.3% | ||
| Q3 24 | — | 17.2% | ||
| Q2 24 | — | 12.6% | ||
| Q1 24 | — | 10.0% |
| Q4 25 | — | $0.32 | ||
| Q3 25 | — | $0.29 | ||
| Q2 25 | $0.01 | $0.17 | ||
| Q1 25 | — | $0.16 | ||
| Q4 24 | — | $0.18 | ||
| Q3 24 | — | $0.14 | ||
| Q2 24 | — | $0.09 | ||
| Q1 24 | — | $0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | $82.8M |
| Total DebtLower is stronger | $0 | — |
| Stockholders' EquityBook value | $83.0M | $171.9M |
| Total Assets | $103.3M | $1.6B |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $82.8M | ||
| Q3 25 | — | $201.9M | ||
| Q2 25 | $37.4M | $191.0M | ||
| Q1 25 | — | $143.7M | ||
| Q4 24 | — | $309.4M | ||
| Q3 24 | — | $114.8M | ||
| Q2 24 | — | $108.7M | ||
| Q1 24 | — | $109.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $0 | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $171.9M | ||
| Q3 25 | — | $169.3M | ||
| Q2 25 | $83.0M | $168.3M | ||
| Q1 25 | — | $168.6M | ||
| Q4 24 | — | $168.3M | ||
| Q3 24 | — | $166.0M | ||
| Q2 24 | — | $166.5M | ||
| Q1 24 | — | $165.8M |
| Q4 25 | — | $1.6B | ||
| Q3 25 | — | $1.6B | ||
| Q2 25 | $103.3M | $1.5B | ||
| Q1 25 | — | $1.5B | ||
| Q4 24 | — | $1.4B | ||
| Q3 24 | — | $1.4B | ||
| Q2 24 | — | $1.3B | ||
| Q1 24 | — | $1.3B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.7M | $9.2M |
| Free Cash FlowOCF − Capex | — | $9.0M |
| FCF MarginFCF / Revenue | — | 94.7% |
| Capex IntensityCapex / Revenue | 0.0% | 2.2% |
| Cash ConversionOCF / Net Profit | -6.24× | 3.55× |
| TTM Free Cash FlowTrailing 4 quarters | — | $14.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $9.2M | ||
| Q3 25 | — | $4.0M | ||
| Q2 25 | $-15.7M | $1.9M | ||
| Q1 25 | — | $-631.0K | ||
| Q4 24 | — | $6.2M | ||
| Q3 24 | — | $861.0K | ||
| Q2 24 | — | $1.4M | ||
| Q1 24 | — | $-429.0K |
| Q4 25 | — | $9.0M | ||
| Q3 25 | — | $4.0M | ||
| Q2 25 | — | $1.8M | ||
| Q1 25 | — | $-649.0K | ||
| Q4 24 | — | $6.2M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $1.3M | ||
| Q1 24 | — | $-449.0K |
| Q4 25 | — | 94.7% | ||
| Q3 25 | — | 44.9% | ||
| Q2 25 | — | 23.0% | ||
| Q1 25 | — | -9.4% | ||
| Q4 24 | — | 86.8% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 21.4% | ||
| Q1 24 | — | -7.2% |
| Q4 25 | — | 2.2% | ||
| Q3 25 | — | 0.8% | ||
| Q2 25 | 0.0% | 0.6% | ||
| Q1 25 | — | 0.3% | ||
| Q4 24 | — | 0.8% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.6% | ||
| Q1 24 | — | 0.3% |
| Q4 25 | — | 3.55× | ||
| Q3 25 | — | 1.65× | ||
| Q2 25 | -6.24× | 1.32× | ||
| Q1 25 | — | -0.49× | ||
| Q4 24 | — | 4.31× | ||
| Q3 24 | — | 0.76× | ||
| Q2 24 | — | 1.75× | ||
| Q1 24 | — | -0.69× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
